| 货号 | 18651-100mg |
| 描述 | Mitotane is an inhibitor of steroidogenesis that suppresses the growth of adrenocortical cells.1,2 It blocks the expression of several genes that encode proteins involved in steroidogenesis and disrupts mitochondrial respiratory chain activity in human adrenocortical cells.1,2 Mitotane has anti-neoplastic actions, alone or in combination with other compounds, and suppresses cortisol synthesis, although it also has significant toxicity in the gastrointestinal tract and nervous system.3,4 It is effective against adrenocortical carcinoma and Cushing’s Syndrome in clinical trials.4,5 |
| 别名 | o,p-DDD;NSC 38721; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Hescot, S.,Slama, A.,Lombès, A., et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocrine-Related Cancer 20(3), 371-381 (2013). 2.Daniel, E., and Newell-Price, J.D.C. Therapy of endocrine disease: Steroidogenesis enzyme inhibitors in Cushing’s syndrome. European Journal of Endocrinology 172(6), R263-R280 (2015). 3.Veytsman, I.,Nieman, L., and Fojo, T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. Journal of Clinical Oncology 27(27), 4619-4629 (2009). 4.Kerkhofs, T.M.A.,Ettaieb, M.H.T.,Hermsen, I.G.C., et al. Developing treatment for adrenocortical carcinoma. Endocr.-Relat.Cancer 22(6), R325-R328 (2015). 5.Kamenicky, P.,Droumaquet, C.,Salenave, S., et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent cushing’s syndrome. Journal of Clinical Endocrinology and Metabolism 96(9), 2796-2804 (2011). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 320 |
| 分子式 | C14H10Cl4 |
| CAS号 | 53-19-0 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |